



ASX Announcement

For immediate release

TALI Health acquisition completed

Melbourne, Australia, Monday 15 February 2016

Key points:

- TALI Health Pty Ltd now 100% owned by Avexa
- Professor Kim Cornish appointed Chair of the Scientific Advisory Board
- Jefferson Harcourt & Benjamin Yeo appointed as Non-Executive Directors
- First clinical trial and game development workshops identified

Avexa Limited (Avexa, ASX: AVX) today advises that it has now completed the acquisition of TALI Health Pty Ltd.

Executive Chairman, Iain Kirkwood said *“we welcome TALI shareholders to Avexa, Professor Kim Cornish as Chair of the Scientific Advisory Board and Jefferson Harcourt and Benjamin Yeo as Non-Executive Directors. We are very pleased to have finally completed the acquisition and we will now look forward to working with our collaborative partners Monash University, Grey Innovation and Torus Games to realise the significant potential of the TALI technology.”*

Professor Kim Cornish, Chair of the Scientific Advisory Board said *“I am very excited to be working with such a talented team and together we will seek to position TALI as the global leader in the profiling, diagnosis and treatment of attention deficits in children.”*

Hannah Kirk, who has joined Avexa as Chief Research Officer is identifying the first clinical trial workshops and first development workshops at key sites to assist with the testing and product development of TALI’s initial suite of modules. The games are designed for children with intellectual and developmental delays, such as Autism and Attention Deficit Hyperactivity Disorder (ADHD), and consist of two key components related to training, diagnosis and treatment of such children.

Iain Kirkwood, Executive Chairman added *“our primary focus is to make available the TALI technology as quickly as possible to medical professionals and educational facilities so we can start helping all those families with kids who are grappling with a range of developmental delay challenges. Because it is delivered via a tablet based “App” we believe we are in a very strong position to*



A V E X A

Avexa Limited
ABN 53 108 150 750
Suite 8, Level 1
61-63 Camberwell Rd
Hawthorn East
Melbourne 3123

Telephone 61 3 8888 1040
Facsimile 61 3 8888 1049
Website www.avexa.com.au

achieve this and meet the growing demand for a new, innovative technology in this critical area of children's healthcare.

END

For more information:

Iain Kirkwood
Executive Chairman
Mob: +61 408 473 496
Avexa: +61 3 8888 1040

www.avexa.com.au